Dyslipidemia Management in Chinese Post Stroke Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01897883|
Recruitment Status : Completed
First Posted : July 12, 2013
Last Update Posted : July 30, 2015
The purpose of this study is to provide current and reliable data of dyslipidimia management together with control situation of blood pressure and glucose for post-stroke patients within 6-12 months from attack, and also the association between patient characteristics and control rate of lipids in this population.
It is an non-interventional study, no study specified treatment is required.Approximately 5000 post ischemic stroke patients within 6-12 months from attack will enter into the study. Fifty centres from different regions of China will participate in this study.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||Dyslipidemia Management in Chinese Post Stroke Patients|
|Study Start Date :||July 2013|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||August 2014|
Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
- To observe LDL-C level of China post-stroke patients within 6-12 months from attack [ Time Frame: Up to 12 months ]Investigator will collect lab test results including blood lipid (i.e. Triglyceride, Total Cholesterol, LDL-C, HDL-C) during the patient visit.
- To observe control rate of LDL-C of China post-stroke patients within 6-12 months from attack [ Time Frame: Up to 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01897883
Show 26 Study Locations
|Principal Investigator:||Yong Jun Wang||Capital Medical University afffiliated Beijing Tiantan Hospital|